Cue Biopharma, Inc. (CUE) Latest Filing Signal

Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, Cue Biopharma, Inc.'s filing signal turned positive.

Cue Biopharma is a clinical-stage biopharmaceutical company focused on developing a novel class of injectable therapeutics designed to selectively engage and modulate disease-specific T cells for autoimmune and inflammatory diseases. Its proprietary Immuno-STAT(R) platform aims to enhance efficacy and minimize off-target effects by selectively modulating disease-relevant T cells. The company's pipeline includes CUE-400 series candidates for autoimmune diseases, CUE-500 series for targeted cell depletion, and CUE-100 series for oncology indications, with some programs licensed to partners like Boehringer Ingelheim and ImmunoScape. Cue Biopharma is preparing to file an Investigational New Drug (IND) application for its lead autoimmune candidate, CUE-401, in the second quarter of 2026.

Revenue is primarily driven by upfront payments, milestone payments, and royalties from collaboration and license agreements with third-party pharmaceutical companies for the development of its drug product candidates.